





ESMO-The CHRISTIE Preceptorship programme on Lung Cancer

3-5 February 2016, Manchester, UK

Co-Chairs:

Fiona Blackhall, UK Raffaele Califano, UK Jean Yves Douillard, FR

Faculty:

Mo Al Aloul, UK - Neil Bayman, UK - Fiona Blackhall, UK Richard Booton, UK - Raffaele Califano, UK Federico Cappuzzo, IT - Clara Chan, UK - Richard Cowan, UK Caroline Dive, UK – Jean-Yves Douillard, FR Corinne Faivre-Fin, UK – Enriqueta Felip, ES – Martin Fruh, CH/ESMO - Marina Garassino, IT Dominique Grunenwald, FR – Jorn Herrstedt, DK Paul Hulse, UK – Keith Kerr, UK - Roit Kochar, UK Jaroslaw Kudzal, PL - Cécile Le Pechoux, FR Catherine McBain, UK - Laura Peberton, UK Miklos Pless, CH - Kandai Seshadri Rammoan, UK Suresh Senan, NL - Hamid Sheik, UK - Rolf Stahel, CH

Yvonne Summers, UK Ben Taylor, UK

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and small cell lung cancer and integrating palliative care in lung cancer treatment





European Society for Medical Oncology

Wednesday, 3 February 2016

| 9.30-10.00 | Registration | | |
|---------------------|---|---|-----|
| 10:00-13:10 190' | Session 1 Screening and Diagnostic for Lung Cancer | Chairs: Keith Kerr, UK/ESMO Raffaele Califano, UK/ESMO | |
| 10.00 | Welcome from The Christie School of Oncology | Richard Cowan, UK | 15' |
| 10.15 | Lung cancer screening: Pro and Contra | Paul Hulse, UK Ben Taylor, UK | 40′ |
| 10.55 | EBUS TBNA in diagnosis/staging of lung cancer | Richard Booton, UK | 30' |
| 11.25 | Coffee break | | 15' |
| 11.40 | Role of pathologist in diagnosis and mutation analysis of lung cancer | Keith Kerr, UK/ESMO | 30' |
| 12.10 | PET/CT in staging of lung cancer | Rohit Kochhar, UK | 30' |
| 12.40 | Medical Thoracoscopy in the management of thoracic malignancies | Mo Al Aloul, UK | 30' |

13.10-14.00 Lunch

| 14:00-16:35 | Session 2 | Chairs: Cécile Le Pechoux, FR/ESMO | |
|-------------|--|------------------------------------|-----|
| 165' | Radical treatment of early stage NSCLC | Dominique Grunenwald, FR/ESMO | |
| 14.00 | Surgery for early stage NSCLC | Dominique Grunenwald, FR/ESMO | 30' |
| 14.30 | Stereotactic ablative RT for early stage NSCLC | Suresh Senan, NL/ESMO | 30' |
| 15.00 | Adjuvant radiotherapy for completely resected | Cécile Le Pechoux, FR/ESMO | 30' |
| | early stage NSCLC | | |
| 15.30 | Coffee break | | 20' |
| 15.50 | Adjuvant chemotherapy for completely | Paul Taylor, UK | 30' |
| | resected early stage NSCLC | | |
| 16.20 | Systemic Treatment of Mesothelioma | Rolf Staehl, CH/ESMO | 30' |
| 16.50 | Close of Day 1 | Chairs | 15' |

Thursday, 4 February 2016

| 09.05-12:40 | Session 3 | Chair: Fiona Blackhall, UK/ESMO | |
|-------------|--|---------------------------------|-----|
| 215' | Advanced NSCLC | Jean Yves Douillard, FR/ESMO | |
| 9.05 | First-line chemotherapy for advanced NSCLC | J Y Douillard, FR/ESMO | 30' |
| 9.35 | Treatment of EGFR mutant advanced NSCLC | Raffaele Califano, UK/ESMO | 30' |
| 10.05 | Second-line treatment for advanced NSCLC | Marina Garassino, IT/ESMO | 30' |
| 10.35 | Coffee break | | 15' |
| 10.50 | Maintenance treatment for advanced NSCLC | Yvonne Summers, UK | 30' |
| 11.20 | Treatment of ALK positive advanced NSCLC | Fiona Blackhall, UK/ESMO | 30' |
| 11.50 | Beyond ALK and EGFR: Novel molecularly | Federico Cappuzzo, IT/ESMO | 30' |
| | driven targeted therapies in NSCLC | | |





European Society for Medical Oncology

| 12.50-13.40 | Lunch | | |
|---------------------|--|---|-----|
| 13:40-16:20 160' | Session 4 Palliative Treatment of Lung Cancer and Mesothelioma | Chairs: Catherine McBain, UK John Herrstedt, DK/ESMO | |
| 13.40 | Treatment of oligometastatic NSCLC | Jaroslaw Kuzdzal, PL/ESMO | 30' |
| 14.10 | Radical treatment of brain metastases: the importance of a neuro-oncology multidisciplinary approach | Catherine McBain, UK | 30' |
| 14.40 | Immunotherapy for lung cancer | Miklos Pless, CH/ESMO | 30' |
| 15.10 | Coffee break | | 20' |
| 15.30 | Intra-luminal Radiotherapy | Hamid Sheikh, UK | 30' |
| 16.00 | Supportive Care in Lung cancer | Jorn Herrstedt, DK/ESMO | 30' |
| 16.30 | Close of Day 2 | Chairmen | 10' |
| 19:30-22:30 | Dinner | | |

Friday, 5 February 2016

| 09:05-12.00 165' | Session 5 Locally advanced NSCLC | Chairs: Corinne Faivre-Finn, UK/ESMO Rohit Shah, UK | |
|---------------------|--|---|-----|
| 9.05 | Role of surgery for N2 disease | K S Rammohan, UK | 30' |
| 9.35 | Combined modality treatment for N2 disease | Clara Chan, UK | 30' |
| 10.05 | Treatment of locally advanced NSCLC in the elderly | Laura Pemberton, UK | 30' |
| 10.35 | Coffee break | | 20' |
| 10.55 | Case-based interactive panel discussion on optimal management of 3 lung cancer cases | Faculty | 65' |
| | Case 1: Neoadjuvant treatment of NSCLC | Ana Roguljić, Croatia | 20' |
| | Case 2: Lock and Key – Dr Eoghan Malone, Ireland | Eoghan Malone, Ireland | 20' |
| | Case 3: NIVOLUMAB, an anti-PD1 checkpoint inhibitor in lung adenocarcinoma. A case report | Giulia Buzzatti, Italy | 20' |
| 12.00-12.50 | Lunch | | |
| 12.50-15.40 160' | Session 6 Focus on Small-Cell Lung Cancer | Chairs: Enriqueta Felip, ES/ESMO Corinne Faivre-Finn, UK/ESMO | |
| 12.50 | Targeted agents in SCLC | Enriqueta Felip, ES/ESMO | 30' |
| 13.20 | Treatment of extensive stage SCLC | Martin Fruh, CH/ESMO | 30' |
| 13.50 | Treatment of limited stage SCLC | Corinne Faivre-Finn, UK/ESMO | 30' |
| 14.20 | Coffee break | | 20' |
| 14.40 | Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC | Neil Bayman, UK, | 30' |
| 15.10 | Versatility of circulating tumour cells in SCLC – biomarkers, biology, mouse models and drug development | Caroline Dive, UK/ESMO | 30' |
| 15.40 | Close of Course | Raffaele Califano, UK/ESMO | 10' |